ICO oral B = AmpB a 2 billion a year drug AmpB works, its been around since the fifties and is the standard against which all other drugs in this class are measured. The problemwith the drug is how it was delivered. It now seems a self-administered (no hospital stay, no toxicity issues), oral formulation of AmpB is attainable. 009 is late pre-clinicalstage. The next steps are to complete preclinical toxicology studies and thenlaunch a Phase 1 safety trial. Gilead Sciences AmpB AmBisome(amphotericin B for liposome injection), were $621 million for the fourth quarter of 2016, compared to $523 million for the same period in 2015
ico 84 million shares so what's it worth a dream target of 500 mil to 1 billion is reasonable for drug companies to buy a drug stock
"these posts are not of a licensed investment advisor or analyst nor does he give out buy, sell or hold advice to anyone"
